Dr. Hope Rugo explains how antibody-drug conjugates like Datroway and Trodelvy are shifting the treatment landscape for ...

Add Yahoo as a preferred source to see more of our stories on Google. Eligible patients had received between one and four previous lines of chemotherapy. Credit: Thomas Andreas via Shutterstock.

DATROWAY demonstrated statistically significant and clinically meaningful improvement in overall survival as 1st-line therapy for patients with metastatic triple-negative breast cancer for whom ...

WILMINGTON, Del., February 03, 2026--(BUSINESS WIRE)--AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for DATROWAY ® (datopotamab deruxtecan-dlnk) has been accepted ...

Datroway received FDA accelerated approval for EGFR-mutated NSCLC after progression on EGFR-targeted therapy and platinum-based chemotherapy. Clinical trials showed a 45% overall response rate and a ...

DATROWAY ® has been approved in the US for the treatment of adult patients with locally advanced or metastatic EGFR- mutated non-small cell lung cancer who have received prior EGFR- directed therapy ...

Positive high-level results from the TROPION-Breast02 phase III trial showed Datroway (datopotamab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement for the ...

Add Yahoo as a preferred source to see more of our stories on Google. AstraZeneca and Daiichi Sankyo's ADC AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC), Datroway (datopotamab ...

AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for DATROWAY®(datopotamab deruxtecan-dlnk) has been accepted and granted Priority Review in the US for the treatment ...

Based on TROPION-Lung05 results and supported by data from TROPION-Lung01 First and only TROP2-directed therapy approved in the US for the treatment of lung cancer WILMINGTON, Del.--(BUSINESS WIRE)-- ...